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Abstract
In order to study the involvement of DNA topoisomerase I (top1) in recombination, we examined the effect of the anti-
neoplastic drug camptothecin, which selectively poisons top1 by trapping top1-cleavable complexes on integration of
exogenic vector into the genome of mammalian cells. We transfected mouse F9 teratocarcinoma cells as well as Chinese
hamster V79 cells with a plasmid carrying a selectable neo gene treated with camptothecin, and determined the frequency of
neo+ (G418R) colonies. We found that treatment with camptothecin for as short a time as 4 h after electroporation resulted in
a 4- to 33-fold stimulation of plasmid integration into the recipient genome via non-homologous recombination. These
results imply that top1-cleavable complexes trapped by camptothecin could be potentially recombinogenic structures and
could stimulate non-homologous recombination in vivo, promoting the integration of transfected plasmids into mammalian
genome. ß 2000 Elsevier Science B.V. All rights reserved.
Keywords: Topoisomerase 1; Non-homologous recombination; Transfected DNA; Camptothecin; Mammalian somatic cell
Mammalian cells possess a high activity of illegit-
imate (non-homologous) recombination that occurs
with little or no dependence on sequence homology
of DNA molecules [1]. When DNA is transfected
into mammalian cells, illegitimate recombination is
a predominant pathway of integration of transfected
DNA into the host genome [2^4]. The mechanism of
such recombination events is poorly understood,
although it presumably involves transient chromoso-
mal DNA strand breaks [5,6].
Topoisomerases are the enzymes that solve topo-
logical and conformational changes in DNA mole-
cules by introducing and rejoining transient, enzyme-
bridged breaks on DNA strands [7].
DNA topoisomerase 1 (top1) creates transient
DNA single-strand breaks by the formation of a co-
valent bond between the 3P-phosphate of the cleav-
age strand and a tyrosine residue of the enzyme. The
anti-neoplastic drug camptothecin selectively poisons
top1 by trapping top1-cleavable complexes, e.g. top
1-linked DNA single-strand breaks with 5P-hydroxyl-
and 3P-top1-linked termini. It has been shown that
top1^DNA cleavage complexes are kinetically com-
petent to ligate added DNA fragments carrying free
5P-OH ends, e.g. mediate illegitimate recombination
in an in vitro assay [8,9].
Moreover, several investigations suggest a role for
eukaryotic top1 in illegitimate recombination in
mammalian somatic cells [10,11]. Bullock et al. found
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that nucleotide sequences surrounding exchange sites
for simian virus 40 prophage excision (a model of
illegitimate event) resemble the loosely conserved
cleavage motif of cellular top1, and that the sequen-
ces at the crossovers are actually cleaved in vitro by
the puri¢ed enzyme [10].
In order to study the involvement of DNA top1 in
recombination, we examined the e¡ect of top1 inhib-
itor camptothecin on the frequency of random inte-
gration of exogenic vector pRV9.1 into genome of
somatic mammalian cells. The plasmid pVR9.1,
kindly provided by Dr. K. Thomas and Dr. M. Ca-
pecchi (University of Utah, USA), contains the frag-
ment of hprt gene 9.1 kb with insertion of the select-
able marker-neo gene [12]. The neo gene renders cells,
which acquired a functional copy of the gene by the
integration of transfected vector into host genome,
resistant to the cytotoxic drug G418. We transfected
Chinese hamster V79 cells with the plasmid pRV9.1
by electroporation, treated the cells with campthote-
cin and estimated the frequency of G418R colonies.
Prior electroporation growing cells were tryp-
sinized, washed with Eagle’s medium and counted.
In each experiment, 10U106 cells were mixed with
50 Wg of the pRV9.1 plasmid and electroporated at
1.08 kV and 0.2 WF. We used closed-circular pRV9.1
plasmid as well as the plasmid digested by BglII en-
donuclease. Under these conditions, 50 þ 10% of the
cells survived the procedure. Then cells were placed
in pre-warmed complete medium with various con-
centrations of the camptothecin for 4 h.
After treatment, the cells were plated on the Ea-
gle’s medium supplemented with 10% of bovine se-
rum and cultured for 4^5 days; then cells were tryp-
sinized, counted and plated on the growth medium
containing 500 Wg/ml of G418 at 200 000/per £ask;
the cells were cultured for 12^14 days to select for
G418-resistant (G418R) colonies.
Fig. 1. Enhancement of random integration of transfected
pRV9.1 plasmid into V79 cells by treatment with camptothecin.
(A) V79 cells were transfected with pRV9.1 by electroporation
and treated with the indicated concentrations of camptothecin
for 4 h as described in the text. Then the drug was removed
and aliquots of the cells were cultured in G418 medium for 5^7
days to select for G418R colonies. The recombination fre-
quency, (frequency of G418R colonies) was determined as the
ratio of the number of G418R colonies to the number of cells
plated for the selection. (B) The aliquots of the cells treated
with camptothecin were cultured in complete growth medium
for 5^7 days to determine their surviving fractions. Error bars
represent the S.D. of four determinations.
Fig. 2. Enhancement of random integration of transfected
pRV9.1 plasmid into F9 cells by camptothecin. F9 cells were
transfected with pRV9.1 by electroporation, treated with 4 Wg/
ml camptothecin and the relative recombination frequency was
determined as described in the legend to Fig. 1.
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We estimated the frequency of random integration
of the plasmid as the ratio of the number of G418R
colonies to the number of cells plated for the selec-
tion. Fig. 1A shows the relative recombinant fre-
quency plotted against drug dose. The basal level
of the frequency of illegitimate recombination (fre-
quency of G418R colonies) in V79 cells not treated
with the inhibitor was 5U1034 (seven determina-
tions).
We found that treatment with camptothecin for as
short a time as 4 h after electroporation resulted in
signi¢cant stimulation of plasmid integration into the
recipient genome in a dose-dependent manner. En-
hancement was independent of whether linearized or
closed-circular plasmids were transfected.
At the maximal response dose assayed, camptothe-
cin caused 33-fold or more enhancements. Cell sur-
vival was dramatically decreased with increasing
doses of the drug (Fig. 1B). The maximal enhance-
ment was observed at a concentration which reduced
the surviving fraction to less than 1%. In this case,
the fraction of cells, in which plasmid was integrated
into the chromosomes appeared to be about 1.5%.
We also evaluated the e¡ect of camptothecin on
the frequency of random integration of pRV9.1 plas-
mid into the host genome of F9 embryonic terato-
carcinoma cells. We found that treatment of F9 cells
after electroporation with 4 Wg/ml camptothecin re-
sulted in 4-fold increasing in the frequency of G418r
colonies (Fig. 2).
Thus, enhancement was observed in di¡erent types
of cells suggesting that the camptothecin e¡ect is in-
trinsically general. We concluded that camptothecin
enhanced random integration of transfected DNA
into the genome of mammalian cells.
Fujimaki et al. [13] have not observed the campto-
thecin e¡ect on the frequency of random integration
of transfected DNA into the genome of human cells.
We propose that the di¡erence in results most likely
is explained by the much lower concentration of
camptothecin (0.5 Wg/ml) used in the experiments of
Fujimaki et al.
Our results imply that top1-cleavable complexes
trapped by camptothecin could be potentially recom-
binogenic structures and could stimulate non-homol-
ogous recombination in vivo, promoting the integra-
tion of transfected plasmids into the genome of
somatic mammalian cells.
Alternatively, the enhancement could be the result
of a secondary e¡ect of camptothecin, which induces
replication-dependent DNA lesions and arrests cells
in S and G2 phase of the cell cycle [14].
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